Maybe you have a different definition of head to head. In my world its one drug vs another, mano a mano, you know like imatinib vs dasatinib.
Whether you care to admit it or not, Dr. Kantarjian specifically suggested that Ariad NOT run a large, head to head trial....which IS exactly what you were suggesting.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.